[Management of Graves' orbitopathy: evidence-based recommendations]

Area of Science:

• Ophthalmology
• Endocrinology
• Autoimmune Diseases

Context:

• Graves' orbitopathy (GO) significantly impacts patient quality of life with symptoms like proptosis, pain, and vision loss.
• Suboptimal management of GO is prevalent, necessitating standardized guidelines.
• The European Group On Graves' Orbitopathy (EUGOGO) developed a consensus statement to address these challenges.

Purpose:

• To provide evidence-based recommendations for the multidisciplinary management of Graves' orbitopathy.
• To outline optimal treatment strategies based on disease activity and severity.
• To emphasize the importance of specialized centers for GO patient care.

Summary:

• GO management necessitates referral to multidisciplinary specialist centers.
• Smoking cessation and euthyroidism are mandatory for all patients.
• First-line treatment for optic neuropathy/corneal ulceration is intravenous glucocorticoids; surgery follows if response is poor.
• Moderate-to-severe active GO warrants intravenous glucocorticoids; inactive GO may require surgery.
• Mild GO can be managed expectantly, with specific treatment if quality of life is impaired.

Impact:

• Standardized management protocols aim to improve functional outcomes and vision preservation in GO patients.
• Multidisciplinary care ensures comprehensive treatment addressing both ophthalmic and endocrine aspects of GO.
• Adherence to EUGOGO guidelines can lead to more effective and consistent GO management globally.